79 results about "Structural biology" patented technology

Provided are novel nanostructures comprising hollow nanospheres and nanotubes for use as chemical sensors and molecular specific photothermal coupling agents. The nanostructures can be used in laser-induced phototherapy for treatment of cancer and other disorders. The nanostructures can also be used as a sensor that detects molecules. The nanostructures are of particular use in the fields of clinical diagnosis, clinical therapy, clinical treatment, and clinical evaluation of various diseases and disorders, manufacture of compositions for use in the treatment of various diseases and disorders, for use in molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof. The hollow gold nanospheres have a unique combination of spherical shape, small size, and strong, tunable, and narrow surface plasmon resonance absorption covering the entire visible to near IR region.

The invention herein disclosed provides for devices and methods that can detect and control an individual polymer in a mixture is acted upon by another compound, for example, an enzyme, in a nanopore. Of particular note is the stability of the system in a saline medium and to detect individual nucleotide bases in a polynucleotide in real time and which may be used to sequence DNA for many hours without change of reagents. The invention is of particular use in the fields of forensic biology, molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof.

The invention relates to the field of biochemistry, molecular biology, structural biology and medicine. More in particular, the invention relates to cross-β structures and the biological role of these cross-β structures.

Provided are novel nanostructures comprising hollow nanospheres (HGNs) and nanotubes for use as chemical sensors, molecular specific photothermal coupling agents, and photothermal ablation compounds. The nanostructures can be used in electromagnetic radiation-induced phototherapy for treatment of cancer and other disorders. The nanostructures can also be used as a sensor that detects molecules. The nanostructures are of particular use in the fields of clinical diagnosis, clinical therapy, clinical treatment, and clinical evaluation of various diseases and disorders, manufacture of compositions for use in the treatment of various diseases and disorders, for use in molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof. The hollow gold nanospheres have a unique combination of spherical shape, small size, and strong, tunable, and narrow surface plasmon resonance absorption covering the entire visible to near IR region.

The invention pertains to the field of structural biology and relates to a process to compare various three-dimensional (3D) structures and to identify functional similarities among them. The process of comparison of 3D atomic structures of the invention is based on the comparisons of defined chemical groups onto the 3D atomic structures and allows the detection of local similarities even when neither the fold nor sequence for example aminoacid sequences for polypeptides sequences or nucleotide sequences for nucleic acid sequences are conserved. This process requires the attribution of selected physico-chemical parameters to each atom of a 3D atomic structure, then the representation of each 3D atomic structure by a graph of chemical groups.

The invention relates to the field of biochemistry, molecular biology, structural biology and medicine. More in particular, the invention relates to cross-β structures and the biological role of these cross-β structures.

The invneiton relates to expression, purification and crystallization of urokinase catalytic domain mutant, relating to the field of medicine, biotechnique, and structural biology. And the invention provides a techical method of expression, purification and crystallization of urokinase catalytic domain mutant in Pichia pastoris. And the cultured urokinase catalytic domain mutant has crystallographic space group R3, and unit cell parameters: a=b=120.48, c=42.45, alpha=beta=90.0deg, and gama=120.0 deg. And this protein has serine proteinase activity, appliable to high flux screening of urokinase inhibitor; and its high resolution crystal provides a research and development platform for design and development of urokinase inhibitor.

The invention discloses a cryoelectron microscope atomic model structure building method and system based on deep learning and application. The method comprises the steps of: 1, obtaining a cryoelectron microscope density map data set, and carrying out model training and model testing; 2, inputting a cryoelectron microscope density map and a corresponding amino acid sequence; and 3, carrying out feature coding and extraction on the cryoelectron microscope density map and the corresponding amino acid sequence, and building an atomic structure model. According to the measurement method provided by the invention, the generated amino acid atom model has structural biological characteristics, the structural biological rationality of the predicted amino acid atom model is ensured, accurate prediction of the end-to-end all-differentiable amino acid internal atom structure is finally realized, certain superiority is achieved, and the atomic model effect predicted by a plurality of tests is verified. In addition, the improvement effect in model building in middle and low resolution is also very obvious.

The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.

The present invention relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present invention relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present invention can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.

The invention belongs to the field of zoonosis researches, and relates to a method for preparing a vaccine of zoonosis. In the method, an HA gene in a cDNA sequence of a type A H1N1 California virus strain (A/California/08/2009(H1N1)) is selected as a research content; the method comprises the following steps of: firstly, analyzing a sequence of the part of an HA protein leaked outside an envelope according to structural biology software; secondly, selecting a part with high immunogenicity according to an antigenic analysis, and constructing a prokaryotic expression vector pGEX-6P-1-HA by using a genetic fragment obtained through a gene synthesis method; and thirdly, converting a masculine recombinant plasmid into Escherichia coli to obtain a recombinant strain (Escherichia coli BL21 rosseta/pGEX-6P-1-HA truncated protein). Through a plurality of chromatography methods, a purified HA truncated protein of the H1N1 is obtained; and by utilizing the expression vector and an adjuvant together to immune organisms, the protective effect on the H1N1 virus is achieved.

The relationship between an amino acid sequence of a protein and its three-dimensional structure is at the very core of structural biology and bioinformatics. The occurrence and conservation of non-canonical conformations is a “local” phenomenon, i.e., non-canonical conformations are encoded intra-helically by short peptide sequences (heptapeptides at most). Effective descriptors can be formed for these short sequences employing training sets. Multiple, distinct patterns are created representing these sequences. A composite descriptor is formed by selecting from among the patterns discovered. The composite descriptor has a high level of sensitivity and specificity while, at the same time, a boosted signal-to-noise ratio.

The invention discloses an epitope polypeptide combination capable of inducing immunity and application thereof, belongs to the technical field of biology, and aims to carry out molecular design of related vaccines by utilizing immunoinformatics on the basis of epitope analysis optimization. Based on a structural antigen epitope vaccine design strategy, a B cell epitope, a Th epitope and a CTL epitope on a new coronavirus S protein are determined through immunoinformatics to induce a main neutralizing antibody, activate cellular immune response and induce body fluid and cellular immune balance. The epitope vaccine is designed through connection of a molecular adjuvant and candidate antigen epitopes, antigenicity, physicochemical properties, protein secondary structure and tertiary structure modeling of the epitope vaccine are analyzed, vaccine conformation B cell epitopes are analyzed by means of a structural biological tool, and immune response characteristics of the vaccine are verified through molecular docking with TLR4 and immune response simulation stimulation. Information analysis results show that the designed candidate epitope combination has well balanced humoral immune and cellular immune response capabilities.

An improved method for producing humanized antibody or an antigen binding fragment thereof is described. The method, designated framework-assembly, bypasses the reliance on structural biology and the construction of large libraries. It is easier to implement and more efficient than the rational design and empirical methods. Also described are humanized antibodies produced by the method and related framework-assembly library.

The invention relates to a construction method of Escherichia coli cold shock assistant dissolving type expression plasmids, and a method for preparing a water-soluble heterogenous polypeptide by applying the Escherichia coli cold shock assistant dissolving type expression plasmid. The cold shock assistant dissolving type expression plasmids for realizing small ubiquitin modified protein (SUMO) and exogenous gene fusion expression under the control of a promoter of a cold shock gene is constructed by using a seamless cloning technology. A chimeric cysteine desulfurase is cloned into the plasmids, such as widely-known pCold I and PET28 series plasmids, to obviously improve the water solubility, the stability and the enzyme activity of recombinant proteins. The SUMO has no influences on thetarget protein space conformation of widely-known pCold TF plasmids. The cutting efficiency of an SUMO label is more than 95% when enzyme digestion is performed at 25 DEG C for 1 h according to a ratio of Ulp1 protease to the recombinant protein of 1 U : (0.5-1) mg, so the Escherichia coli cold shock assistant dissolving type expression plasmids are very suitable for preparing proteins having natural N ends in the fields of bioengineering pharmacy and structural biology.

The invention relates to the technical field of vaccine preparation, and especially relates to a recombinant avian influenza subunit vaccine and a preparation method thereof. A head structure in a main protective antigen HA skeleton of H5 subtype avian influenza is reserved, and a neck area of a vaccine H5 is replaced with an influenza HA neck area having broad-spectrum immune protection after structural biology design and transformation, so that the neck area can be proved to protect mutant strains of different H5 and provide broad-spectrum protection on H7 in a mouse experiment.

The invention provides a recombinant archaerhodopsin 4 protein. An encoding nucleotide sequence is shown in SEQ ID NO.1, and an amino acid sequence is shown in SEQ ID NO.2. The invention also provides a preparation method of the recombinant archaerhodopsin 4 protein. By utilizing a gene engineering method, an AR4 gene is appropriately modified, and converted into halobacterium L33 for performing protein expression. The invention also provides application of the recombinant archaerhodopsin 4 protein in structural biology research.

The invention discloses an anti-tumor application of 3-{2-[([1,1'-biphenyl]-4-methyl)amino]-1-ethoxy}phenol. The 3-{2-[([1,1'-biphenyl]-4-methyl)amino]-1-ethoxy}phenol low molecular weight compound is screened out through a candidate medicine screening platform combining structural biology, bioinformatics and biology activity testing and can be applied to the anti-tumor field, or is combined with other medicines or means so as to be applied to the anti-tumor field. The 3-{2-[([1,1'-biphenyl]-4-methyl)amino]-1-ethoxy}phenol can be used for the targeted inhibition of HAb18G/CD147 protein and can be applied in the preparation of medicines for treating diseases related to HAb18G/CD147 protein high expression (such as tumors, especially liver cancer).

The invention relates to a transcription factor binding site prediction method fusing DNA shape features, belongs to the field of bioinformatics, and provides a new model for predicting transcription factor binding sites by using CNN in combination with DNA sequence and shape feature information by combining knowledge of structural biology, genomics and a deep learning neural network. Meanwhile, a special data set containing DNA shape features and DNA sequence information is constructed, and corresponding DNA shape information is added on the basis of a traditional transcription factor prediction data set. Therefore, the prediction accuracy of the DNA transcription factor binding site is improved.